$0.01
+0.00%Price chart
Aug 12Aug 19Aug 24Aug 27Sep 1Sep 9Sep 15Sep 18
Key dataSep 18, 2026
Open$0.08
From 52W high−96.55%
Volume7472.00
Market cap$82900.00
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.08
From 52W high
−96.55%
Volume
7472.00
Market cap
$82900.00
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
32.5
MomentumView details →
1D Return
+0.00%
YTD Return
−87.53%
SummaryUpdated Jun 1, 2026
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company founded in 2020 and based in Redwood City, California. The company specializes in developing innovative therapeutic agents for hematopoietic stem cell transplantation and gene therapies, with a focus on conditioning agents and stem cell engineering technologies. Since going public in January 2020, Jasper has been advancing its pipeline of experimental treatments designed to expand the use of stem cell transplantation and improve outcomes for patients requiring these life-saving procedures.
Similar companies
Latest newsMore news →
Jasper Therapeutics appointed Lisa Pitt as Senior Vice President, Regulatory Affairs and Shiguang Liu as a clinical executive.5d agoJasper Therapeutics reported a net loss of $2.76 million for Q2 2026, with diluted loss per share of $0.10, and cash and cash equivalents of $7.3 million as of June 30, 2026.38d agoJasper Therapeutics raised $132 million in a private stock offering.66d ago